Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
2,666,933
-
Total 13F shares
-
17,340
-
Share change
-
+17,340
-
Total reported value
-
$101,452
-
Price per share
-
$5.88
-
Number of holders
-
5
-
Value change
-
+$101,452
-
Number of buys
-
5
Institutional Holders of LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) as of Q2 2023
As of 30 Jun 2023,
LIXTE BIOTECHNOLOGY HOLDINGS, INC. - Common Stock, par value $0.0001 per share (LIXT) was held by
5 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,340 shares.
The largest 5 holders included
GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, UBS Group AG, Tower Research Capital LLC (TRC), and WELLS FARGO & COMPANY/MN.
This page lists
5
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.